A study on the effectiveness and safety of two dosing regimens of the drug Cernilton® in patients with chronic nonbacterial prostatitis was performed. The patients were randomized into two groups. Group I (55 patients) received Cernilton 2 tablets 3 times a day, group II (23 patients) received Cernilton 1 tablet 3 times a day. When analyzing the number of leukocytes in the prostatic secretion we indicated a decrease in their number per field of view at the third visit as compared with the first visit by 71% (p <0,001) in the first group, while in the second group – by 65% (p <0,001).
When analyzing urodynamic parameters in group I at the third visit compared with the first visit an increase in Qmax by 3% (p = 0,55) and decrease of residual urine by 66% (p = 0,03) have been indicated. In group II at the third visit compared with the first visit we indicated an increase in Qmax by 1,5% (p = 0,66) and a decrease in residual urine by 100% (p = 1,0).
In the first group when analyzing the prostate volume according to transrectal ultrasonography reduction of prostate volume was observed at the third visit compared with the first visit by 9% (p = 0,01). In the second group during the same period an increase of the prostate volume by 0,5% (p = 0,92) was detected.
A comparative analysis of the effectiveness of two dosing regimens of Cernilton in treatment of patients with chronic nonbacterial prostatitis revealed significant difference in subjective sensation of patients (using the NIH-CPSI scale and symptom frequency scale).
An analysis of subjective (according to the NIH-CPSI scale, symptom frequency scale, linear scale, Sex-4, I-PSS, QOL) and objective (number of leukocytes in the prostatic secretion) data demonstrated that Cernilton ® has a pronounced anti-inflammatory effect and furthermore its treatment response lasts at least for 6 months.